Global Submissions Strategy: Aligning for Divergence in Oncology Drug Development

Global Strategies for Oncology Submissions

Explore strategies for ensuring that oncology data submitted to US FDA, worldwide regulators, and health technology assessment (HTA) bodies is aligned with the evidence expectations at each agency.

Read the white paper from SSI Strategy for insights on keeping timelines intact while supporting regulatory efficiency and broad access.

Explore:

Evidence expectation divergence across regulatory bodies
Considerations for achieving modularity and flexibility in dossier design structure
Mitigation strategies for sponsors anticipating divergence
Practical and actionable insights into cross-functional considerations for oncology dossiers designed for global use

To access the insights, please complete the form.

Your Company Email Address

Country *

Opt In?

By completing this form you agree Citeline and SSI Strategy may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and SSI Strategy.